Analytical Data
-
Gene name
EID3
- Application
-
Alternative Names
EID3；EP300-interacting inhibitor of differentiation 3
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8N140
-
Expression Region
1-333aa
-
AA Sequence
MKMDVSVRAA GCSDDLSSGE ADVDPKLLEL TADEEKCRSI RRQYRQLMYC VRQNREDIVS SANNSLTEAL EEANVLFDGV SRTREAALDA RFLVMASDLG KEKAKQLNSD MNFFNQLAFC DFLFLFVGLN WMEGDPDKLS DCDDSIALSF WKAIEKEATS WMVKAETFHF VFGSFKLERS APKPRLEHQK KVRKMEENGN MPTKLQKLDL SSYPEATEKN VERILGLLQT YFRKYPDTPV SYFEFVIDPN SFSRTVENIF YVSFIVRDGF ARIRLDEDRL PILEPMNVNQ MGEGNDSSCH GRKQGVISLT LQEWKNIVAA FEISEAMITY SSY
-
Molecular Weight
38.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
EID3 (Emerging Immune Response Protein 3) is an important protein that plays a crucial role in cellular processes, particularly in the immune response and regulation of gene expression. Initially identified as a hypoxia-responsive protein, EID3 has garnered interest due to its involvement in various cellular pathways, including cell cycle regulation and apoptosis. Research indicates that EID3 can interact with key transcriptional regulators and chromatin-modifying complexes, suggesting its role in epigenetic regulation. The study of EID3 is further propelled by its potential implications in cancer biology, where altered expression levels may impact tumor progression and response to therapy. Understanding the structure and function of EID3 can provide insights into novel therapeutic strategies aimed at modulating immune responses and targeting cancer cells. Additionally, elucidating the mechanisms through which EID3 exerts its functions may open avenues for developing biomarkers for disease diagnosis and prognosis. Overall, the investigation of EID3 and its recombinant forms holds promise for advancing our understanding of immune regulation and disease mechanisms.
